Sevilay Altıntaş

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung et al. · The Lancet · 2022 · 642 citations · Full text

Medicine, Oncology, Pharmacology +16

Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia

Laurent Bastit, A. Vandebroek, Sevilay Altıntaş et al. · Journal of Clinical Oncology · 2008 · 195 citations · Full text

Medicine, Hematology, Pharmacology +17

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group

Hans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago et al. · The Lancet Oncology · 2018 · 129 citations

Medicine, Oncology, Pharmacology +17

Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994

Gemma G. Kenter, Stefano Greggi, Ignace Vergote et al. · Journal of Clinical Oncology · 2023 · 95 citations · Full text

Medicine, Oncology, Surgery +17

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

Christian Marth, Ignace Vergote, Giovanni Scambia et al. · European Journal of Cancer · 2016 · 80 citations

Medicine, Oncology, Pharmacology +13